The European Medicines Agency was this week due to consider requests from four companies that want it to fast-track its reviews of their planned EU drug marketing authorization applications (MAAs), including one from Eli Lilly for its Alzheimer’s disease drug candidate, donanemab.
EMA Deciding If Donanemab For Alzheimer’s & Three Other Drugs Merit Fast-Tracking
Eli Lilly, MSD, CLS and Pfizer could this week find out if the European Medicines Agency will agree that their planned EU marketing applications for donanemab, sotatercept, garadacimab and aztreonam-avibactam respectively deserve an accelerated assessment.
